Trius Therapeutics' P2P Acquisition

Trius Therapeutics raised a round of funding on September 12, 2013. Investors include Cubist Pharmaceuticals.

Trius Therapeutics is discovering and developing antibacterial drugs for the treatment of life-threatening infections. The company's lead product candidate, TR-701 is a oral and IV oxazolidinone antib…

Articles about Trius Therapeutics' P2P Acquisition: